Biotechs juggle dilution, debt, and daring fundraising moves
The gist
Biotechs are pulling out all the stops—from high-octane equity lines to debt gymnastics—to keep their balance sheets afloat in a brutal funding climate.
What to know
- IQSTEL Inc. tapped a $50 million equity line and issued dividend-heavy preferred stock to execs, boosting liquidity while risking major shareholder dilution.
- BioXcel Therapeutics is teetering on the edge with just $13.8 million in cash versus $107.2 million in debt and a $115 million deficit, scrambling for lifelines but with no committed deals yet.
- Oxford Biodynamics, BiomX, Instinct Biotechnical, and Latigo Bio all made big capital moves—ranging from discounted share placings to $150 million financing—to buy time and keep innovation alive amid market turbulence.
Creative Dilution Tactics
Biotechs are using equity lines, preferred stock, and milestone payments in shares to preserve cash, even as these moves sharply dilute existing shareholders and reshape executive incentives.
IQSTEL Inc. has strategically leveraged a $50 million equity line alongside preferred stock issuances to bolster liquidity, securing written consent to issue common stock exceeding 19.99% of shares outstanding without convening a shareholder meeting. This maneuver, fully compliant with Nasdaq and Nevada corporate rules, enables significant capital raising but comes at the cost of substantial dilution to existing common shareholders, reflecting the delicate balance biotech firms must strike between funding needs and shareholder interests.
In a bid to align management incentives with shareholder value amid funding pressures, IQSTEL replaced prior common stock incentives with richly structured Series B Preferred Stock awards to its CEO and CFO, featuring a 24% dividend and favorable conversion terms. This shift underscores how preferred stock can serve dual purposes: attracting capital and motivating leadership to navigate challenging market conditions effectively.
Exicure exemplifies a growing trend among biotech firms to conserve cash by settling milestone payments with equity, issuing 172,058 shares to cover a $1 million obligation and thereby preserving liquidity amid a precarious $2.6 million cash balance. Although this approach dilutes shareholders by approximately 2.7% and follows a steep 74% stock price decline, it is deemed a necessary trade-off to sustain development of promising drug candidates like Burixafor and maintain financial flexibility during critical pivot points.
Oxford Biodynamics is deploying a conditional equity placing to raise £9.15 million at a 9.1% discount, contingent on shareholder approval, to secure at least twelve months of working capital and advance a refreshed commercial strategy focused on diversified revenue streams. CEO Richard Compton’s approach highlights how discounted equity raises not only address immediate liquidity needs but also underpin strategic growth initiatives in a funding-constrained biotech landscape.
Debt Swaps and Survival
Companies are restructuring debt through share issuances and creative settlements, trading near-term liquidity relief for dilution and regulatory risk as they scramble to avoid insolvency.
BiomX's amendment of its $1.25 million promissory note tied to the Zorronet acquisition exemplifies a strategic debt restructuring approach that blends extending payment terms with share-based settlements. By issuing 800,000 restricted shares to Water.IO Ltd. as payment for accrued interest and extending the note's maturity to November 1, 2026, BiomX secured vital liquidity relief and a structured payment schedule, including an initial $250,000 followed by four monthly installments. However, this maneuver, while easing immediate cash flow pressures, introduces risks such as shareholder dilution, liquidity constraints, and potential non-compliance with NYSE American listing standards, underscoring the delicate balance biotech firms must strike between operational runway extension and financial governance.
BioXcel Therapeutics faces a critical liquidity crunch with only $13.8 million in cash to fund operations through August 2026 against a daunting $107.2 million debt load and a stockholders’ deficit exceeding $115 million. The company’s urgent pursuit of debt restructuring, asset sales, mergers, and additional financing reflects the high-stakes challenge of managing negative working capital of $108.4 million while striving to avoid insolvency. Despite exploring multiple strategic alternatives, BioXcel has yet to secure a committed transaction, highlighting the complex and uncertain path biotech firms navigate when attempting to recalibrate their capital structures under severe funding pressures.
Quantum BioPharma's recent debt-for-equity swap, settling CAD$123,487.43 of outstanding obligations through the issuance of Class B subordinate voting shares, illustrates a tactical move to alleviate immediate financial liabilities by converting debt into equity. The issuance price, pegged to the lower of CAD$4.26 or the Canadian Securities Exchange closing price prior to settlement, ties the debt conversion value directly to market performance, aligning creditor interests with shareholder outcomes. However, the lack of U.S. securities registration for these shares restricts their liquidity and tradability within the U.S. market, reflecting a trade-off between debt relief and market access that companies must weigh carefully in cross-border capital maneuvers.
Tailored Capital Raises
From discounted placings to nine-figure financings, biotechs are customizing fundraising strategies to fuel growth, retain rights, and attract big-pharma partners amid volatile markets.
Instinct Biotechnical’s $150 million equity purchase facility, announced in late July 2026, underscores a strategic approach to maintaining financial agility in a constrained funding environment. CEO Tomoki Nagano highlighted that this three-year facility enables the company to sell common stock as needed to fund development, working capital, and acquisitions, thereby balancing immediate financing needs with long-term growth objectives. Similarly, Oxford BioDynamics’ conditional £9.15 million share placing in August 2026, offered at a 9.1% discount and pending shareholder approval, reflects a targeted capital raise to sustain commercial priorities such as expanding platform partnerships and advancing clinical adoption of their CiRT technology, illustrating how companies are tailoring fundraising to specific operational milestones.
Latigo Bio’s robust $150 million Series B financing round in August 2026 exemplifies how late-stage biotech firms are securing substantial capital injections to navigate market volatility and fuel strategic growth. The simultaneous hiring of a new CFO with prior ties to the company signals an intentional gearing up for future fundraising efforts, including potential public offerings, demonstrating a dual focus on immediate capital needs and long-term financial positioning. This mirrors Reclutex’s earlier Series B round in January 2026, which brought in strategic investors Eli Lilly and Sanofi, showcasing a trend where biotech companies diversify funding sources through partnerships with established pharma players to bolster resilience amid private funding challenges.
Sana Bio’s fundraising narrative highlights the critical balance between securing sufficient capital and retaining full global rights to their complex cell therapy programs. Despite holding $180 million in cash as of mid-2026, the company openly acknowledges the necessity for additional funding to sustain ongoing development and strategic expansion. This candid approach underscores the broader biotech sector’s challenge of aligning scientific promise with financial realities, where securing flexible yet substantial capital remains essential to advancing innovative therapies without compromising intellectual property control.
Oxford BioDynamics’ refreshed commercial strategy, articulated by CEO Richard Compton, complements its fundraising efforts by focusing on four distinct revenue streams—platform services, healthcare programs, pharma partnerships, and diagnostic collaborations—to drive sustainable, partnership-led growth. This strategic pivot, coupled with the recent capital raise, reflects a deliberate effort to not only secure immediate working capital but also to build a diversified and resilient business model that can withstand ongoing funding pressures while advancing clinical and commercial objectives.
Liquidity on the Brink
Even aggressive cost cuts and direct offerings are failing to offset massive losses and looming debt maturities, leaving some biotechs’ survival in doubt without urgent new capital.
Insight Molecular Diagnostics illustrates the acute operational challenges biotech firms face, grappling with a steep revenue plunge to $271,000 alongside a hefty $15.6 million net loss year-to-date. Yet, through a strategic $24.6 million registered direct offering in early 2026, including investment from Bio-Rad, the company bolstered its cash position to $17.8 million and narrowed its shareholder deficit, demonstrating how targeted financing and cost controls can extend liquidity runway despite ongoing cash burn and operating losses.
BioXcel Therapeutics confronts a far more dire liquidity crunch as of August 2026, with only $13.8 million in cash to sustain operations through the month against a looming $107.2 million debt maturity due August 21. The company’s financial strain is starkly reflected in its negative working capital of $108.4 million and a stockholders’ deficit of $115.5 million, casting substantial doubt on its ability to continue as a going concern and underscoring the critical need for urgent capital infusion.
Despite some commercial traction from its drug IGALMI and efforts to reduce R&D expenses, BioXcel acknowledges that these measures fall short of addressing its massive debt obligations and sustaining its development pipeline. The company is actively exploring a broad spectrum of strategic alternatives—including debt restructuring, additional financing, asset sales, and mergers—but the absence of any committed deal highlights the precariousness and uncertainty enveloping its liquidity strategy.